These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 33622158)

  • 1. Teprotumumab and hearing loss: hear the warnings.
    Chern A; Gudis DA; Dagi Glass LR
    Orbit; 2021 Aug; 40(4):355-356. PubMed ID: 33622158
    [No Abstract]   [Full Text] [Related]  

  • 2. Teprotumumab and Hearing Loss: Case Series and Proposal for Audiologic Monitoring.
    Belinsky I; Creighton FX; Mahoney N; Petris CK; Callahan AB; Campbell AA; Kazim M; Lee HBH; Yoon MK; Dagi Glass LR
    Ophthalmic Plast Reconstr Surg; 2022 Jan-Feb 01; 38(1):73-78. PubMed ID: 34085994
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thyroid Eye Disease, Teprotumumab, and Hearing Loss: An Evolving Role for Otolaryngologists.
    Chern A; Dagi Glass LR; Gudis DA
    Otolaryngol Head Neck Surg; 2021 Dec; 165(6):757-758. PubMed ID: 33781112
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rifle Blast Exacerbating Hearing Loss in a Patient Treated With Teprotumumab for Thyroid Eye Disease.
    Reed DS; Kostosky N; Davies BW; Epstein A; Durairaj VD
    Ophthalmic Plast Reconstr Surg; 2022 Mar-Apr 01; 38(2):e41-e43. PubMed ID: 34652314
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Teprotumumab-associated chronic hearing loss screening and proposed treatments.
    Chow A; Silkiss RZ
    BMJ Case Rep; 2022 Apr; 15(4):. PubMed ID: 35418378
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Teprotumumab for the treatment of thyroid eye disease.
    Ju Y; Yang J
    Expert Rev Clin Immunol; 2020 Aug; 16(8):739-743. PubMed ID: 32707005
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised, double-masked, placebo-controlled, multicentre trials.
    Kahaly GJ; Douglas RS; Holt RJ; Sile S; Smith TJ
    Lancet Diabetes Endocrinol; 2021 Jun; 9(6):360-372. PubMed ID: 33865501
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Teprotumumab: Interpreting the Clinical Trials in the Context of Thyroid Eye Disease Pathogenesis and Current Therapies.
    Winn BJ; Kersten RC
    Ophthalmology; 2021 Nov; 128(11):1627-1651. PubMed ID: 33930408
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rapidly progressive cognitive decline associated with teprotumumab in thyroid eye disease.
    Hoang TD; Nguyen NT; Chou E; Shakir MK
    BMJ Case Rep; 2021 May; 14(5):. PubMed ID: 33972303
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Teprotumumab: First Approval.
    Markham A
    Drugs; 2020 Apr; 80(5):509-512. PubMed ID: 32157641
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and Exposure-Response Relationship of Teprotumumab, an Insulin-Like Growth Factor-1 Receptor-Blocking Antibody, in Thyroid Eye Disease.
    Xin Y; Xu F; Gao Y; Bhatt N; Chamberlain J; Sile S; Hammel S; Holt RJ; Ramanathan S
    Clin Pharmacokinet; 2021 Aug; 60(8):1029-1040. PubMed ID: 33768488
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Teprotumumab and Hyperglycemia Guidelines to Monitor for Hyperglycemia in Teprotumumab.
    Lee HBH; Mariash CN; Yoon MK; Belinsky I; Creighton FX; Mahoney N; Petris CK; Callahan AB; Campbell AA; Kazim M; Dagi Glass LR
    Ophthalmic Plast Reconstr Surg; 2021 Jul-Aug 01; 37(4):393. PubMed ID: 34229337
    [No Abstract]   [Full Text] [Related]  

  • 13. Teprotumumab for the Treatment of Active Thyroid Eye Disease.
    Douglas RS; Kahaly GJ; Patel A; Sile S; Thompson EHZ; Perdok R; Fleming JC; Fowler BT; Marcocci C; Marinò M; Antonelli A; Dailey R; Harris GJ; Eckstein A; Schiffman J; Tang R; Nelson C; Salvi M; Wester S; Sherman JW; Vescio T; Holt RJ; Smith TJ
    N Engl J Med; 2020 Jan; 382(4):341-352. PubMed ID: 31971679
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Teprotumumab, an IGF-1R blocking monoclonal antibody inhibits TSH and IGF-1 action in fibrocytes.
    Chen H; Mester T; Raychaudhuri N; Kauh CY; Gupta S; Smith TJ; Douglas RS
    J Clin Endocrinol Metab; 2014 Sep; 99(9):E1635-40. PubMed ID: 24878056
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hear this! Audiometry testing saves the hearing of a patient with drug-resistant tuberculosis.
    Tesema E; Wares F; Bedru A; Negeri C; Molla Y; Kassa A; Ayele B; Siraj H; Tsegaye F
    Int J Tuberc Lung Dis; 2019 Mar; 23(3):378-379. PubMed ID: 30871670
    [No Abstract]   [Full Text] [Related]  

  • 16. Hearing improvement after bevacizumab for neurofibromatosis type 2.
    Guntinas-Lichius O
    N Engl J Med; 2009 Oct; 361(18):1809-10; author reply 1810-1. PubMed ID: 19864683
    [No Abstract]   [Full Text] [Related]  

  • 17. Use of teprotumumab in thyroid eye disease.
    Greenhill C
    Nat Rev Endocrinol; 2021 Jul; 17(7):383. PubMed ID: 33953374
    [No Abstract]   [Full Text] [Related]  

  • 18. Teprotumumab in Thyroid-Associated Ophthalmopathy: Rationale for Therapeutic Insulin-Like Growth Factor-I Receptor Inhibition.
    Smith TJ
    J Neuroophthalmol; 2020 Mar; 40(1):74-83. PubMed ID: 32040069
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Teprotumumab for thyroid-associated ophthalmopathy : OPTIC].
    Gärtner R; Nitschmann S
    Internist (Berl); 2020 Nov; 61(11):1208-1210. PubMed ID: 33025123
    [No Abstract]   [Full Text] [Related]  

  • 20. Teprotumumab for Active Thyroid Eye Disease.
    Kim S; Patzek S
    N Engl J Med; 2020 May; 382(20):1958-1959. PubMed ID: 32402170
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.